Equivalent potency of Xeomin® and BOTOX®

Dressler, Dirk; Mander, Gerd J.; Fink, Klaus

doi:10.1016/j.toxicon.2008.04.029

Cited by 10 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activity of these drugs is assessed by lethality assay (LD 50 ), measured in mouse units (MU): However, assays by manufactures differ and preclude direct comparisons of potency between brands [24]. Although the individual units are not interchangeable, generally, one unit of onabotulinumtoxinA is equivalent to one unit of incobotulinumtoxinA [35], 2.5 units of abobotulinumtoxinA [36], and 50 units of rimabotulinumtoxinB [37]. Overall, BoNT-A has greater motor effects while BoNT-B has greater autonomic effects associated, for example, with dryness of the mouth due to reduced salivary secretions [24,38].…”

Section: Botulinum Toxin Structure and Functionmentioning

confidence: 99%

Immunogenicity Associated with Botulinum Toxin Treatment

Bellows

Jankovic

2019

Toxins

132

143

View full text Add to dashboard Cite

Botulinum toxin (BoNT) has been used for the treatment of a variety of neurologic, medical and cosmetic conditions. Two serotypes, type A (BoNT-A) and type B (BoNT-B), are currently in clinical use. While considered safe and effective, their use has been rarely complicated by the development of antibodies that reduce or negate their therapeutic effect. The presence of antibodies has been attributed to shorter dosing intervals (and booster injections), higher doses per injection cycle, and higher amounts of antigenic protein. Other factors contributing to the immunogenicity of BoNT include properties of each serotype, such as formulation, manufacturing, and storage of the toxin. Some newer formulations with purified core neurotoxin devoid of accessory proteins may have lower overall immunogenicity. Several assays are available for the detection of antibodies, including both structural assays such as ELISA and mouse-based bioassays, but there is no consistent correlation between these antibodies and clinical response. Prevention and treatment of antibody-associated non-responsiveness is challenging and primarily involves the use of less immunogenic formulations of BoNT, waiting for the spontaneous disappearance of the neutralizing antibody, and switching to an immunologically alternate type of BoNT.

show abstract

Section: Botulinum Toxin Structure and Functionmentioning

confidence: 99%

Immunogenicity Associated with Botulinum Toxin Treatment

Bellows

Jankovic

2019

Toxins

132

143

View full text Add to dashboard Cite

show abstract

Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm

Wabbels

Reichel²,

Fulford-Smith

et al. 2010

J Neural Transm

View full text Add to dashboard Cite

Botulinum neurotoxins (BoNTs) are the primary treatment for focal dystonias such as blepharospasm. Several different BoNT products are available in various countries. Given the variability in manufacturing, formulation, and unit doses of BoNTs, it is important to compare the profiles of products from different manufacturers. This double-blind, randomised, parallel-group pilot study compared the efficacy and safety of the BoNT type A product Xeomin® from Merz to BOTOX® from Allergan. Subjects (n = 65) were randomly assigned to receive one or the other BoNTA in a 1:1 proportion at a dose equal to that of their most recent treatment (≥20 U/eye). Symptoms were assessed on the Blepharospasm Disability Index (BSDI), Jankovic Rating Scale (JRS), and Patient Global Assessment (PGA) scale at 4 and 8 weeks. Both BoNTA products reduced scores on the BSDI and JRS (no statistically significant difference, tendency toward greater improvements with BOTOX® than Xeomin® at 4 and 8 weeks). A post hoc analysis showed a significantly greater number of BOTOX® treated patients reaching a responder threshold of 4 points on the total BSDI score and 0.67 points on the BSDI mean item score. No significant differences between products were noted in PGA and adverse events at the doses used in this study.

show abstract

Clinical use of botulinum toxins in oral and maxillofacial surgery

Majid

2010

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Equivalent potency of Xeomin® and BOTOX®

Cited by 10 publications

References 0 publications

Immunogenicity Associated with Botulinum Toxin Treatment

Immunogenicity Associated with Botulinum Toxin Treatment

Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm

Clinical use of botulinum toxins in oral and maxillofacial surgery

Contact Info

Product

Resources

About